Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration-Reference-Cited by-同舟云学术

Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration

Published:2016-06-01 Issue:6 Volume:2 Page:744
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Tibau Ariadna¹,Ocana Alberto²,Anguera Geòrgia¹,Seruga Bostjan³,Templeton Arnoud J.⁴,Barnadas Agustí¹,Amir Eitan⁵

Affiliation:

1. Medical Oncology Department, Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, Barcelona, Spain

2. Medical Oncology Department and Translational Research Unit, Albacete University Hospital, Albacete, Spain

3. Sector of Medical Oncology, Institute of Oncology Ljubljana and University of Ljubljana, Ljubljana, Slovenia

4. Medical Oncology Department, Kantonsspital St Gallen, St Gallen, Switzerland

5. Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, Canada

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validity and Reliability of the Turkish Version of National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18) and Neurotoxicity-4 (NTX-4) for Patients with Advanced Ovarian Cancer;European Journal of Cancer Care;2023-11-09

2. Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice;The Lancet Oncology;2023-05

3. Comparing g-computation, propensity score-based weighting, and targeted maximum likelihood estimation for analyzing externally controlled trials with both measured and unmeasured confounders: a simulation study;BMC Medical Research Methodology;2023-01-17

4. Comparing G-Computation, Propensity Score-Based Weighting, and Targeted Maximum Likelihood Estimation for Analyzing Externally Controlled Trials with Both Measured and Unmeasured Confounders: A Simulation Study;2022-09-27

5. Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock;SpringerBriefs in Public Health;2022